参考文献/References:
[1]Pan J,Huang Z,Lin H,et al.M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma[J].BMC Cancer,2022,22(1):1132-1132.[2]Herbst RS,Morgensztern D,Boshoff C.The biology and management of non-small cell lung cancer[J].Nature,2018,553(7689):446-454.[3]黄小明,杜野,林少明,等.呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J].中国临床药理学与治疗学,2023,28(1):66-74.[4]Duma N,Santana-Davila R,Molina JR.Non-Small Cell Lung Cancer: Epidemiology, Screening,Diagnosis, and Treatment[J].Mayo Clin Proc,2019,94(8):1623-1640.[5]Rotoli D,Santana-Viera L,Ibba ML,et al.Advances in Oligonucleotide Aptamers for NSCLC Targeting[J].International Journal of Molecular Sciences,2020,21(17):6075-6075.[6]Wang BJ,Liu DC,Guo QY,et al.NUDT21 Suppresses Breast Cancer Tumorigenesis Through Regulating CPSF6 Expression[J].Cancer Management and Research,2020,12:3069-3078.[7]陈枞,杜俊娴,蔡承哲,等.CPSF6调控Notch信号通路促进破骨细胞分化及乳腺癌骨转移[J].中国临床医学,2020,27(3):422-427.[8]Tan S,Zhang M,Shi X,et al.CPSF6 links alternative polyadenylation to metabolism adaption in hepatocellular carcinoma progression[J].J Exp Clin Cancer Res,2021,40(1):85. [9]Liu Y,Zou H,Xie Q,et al.Ribonucleic acid-binding protein CPSF6 promotes glycolysis and suppresses apoptosis in hepatocellular carcinoma cells by inhibiting the BTG2 expression[J].Biomed Eng Online,2021,20(1):67.[10]黄进,娄哲琦,朱勇.CPSF6在胶质母细胞瘤进展中的作用及相关调控机制研究[J].中国生物工程杂志,2022,42(9):1-16.[11]Shi X,Ding K,Zhao Q,et al.Suppression of CPSF6 Enhances Apoptosis Through Alternative Polyadenylation-Mediated Shortening of the VHL 3’UTR in Gastric Cancer Cells[J].Front Genet,2021,12:707644. [12]Guo S,Wang G,Zhao Z,et al.Deregulated expression and subcellular localization of CPSF6, a circRNA-binding protein, promote malignant development of esophageal squamous cell carcinoma[J].Chin J Cancer Res,2022,34(1):11-27.[13]张武通,韩健康,张海莲.SCCAg、EGFR及NSE在非小细胞肺癌病情进展、预后预测中的价值[J].分子诊断与治疗杂志,2022,14(9):1511-1514,1518.[14]Zhang Y,Liu L,Qiu Q,et al.Alternative polyadenylation: methods, mechanism, function, and role in cancer[J].Journal of Experimental & Clinical Cancer Research,2021,40(1):51-51.[15]Yuan F,Hankey W,Wagner EJ,et al.Alternative polyadenylation of mRNA and its role in cancer[J].Genes & Diseases,2019,8(1):61-72.[16]Wang L,Hu X,Wang P,et al.Integrative 3’ Untranslated Region-Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple-Negative Breast Cancer[J].Oncologist,2019,24(1):22-30.[17]Xiang Y,Ye Y,Lou Y,et al.Comprehensive Characterization of Alternative Polyadenylation in Human Cancer[J].J Natl Cancer Inst,2018,110(4):379-389. [18]Zhang Y,Shen L,Shi Q,et al.Comprehensive Analysis of APA Events and Their Association With Tumor Microenvironment in Lung Adenocarcinoma[J].Front Genet,2021,12:645360-645360.
相似文献/References:
[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(04):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(04):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的
表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(04):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(04):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(04):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[6]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(04):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[7]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(04):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[8]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(04):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[9]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
[10]杨珑静,马洪波,张献全.抗血管生成药物在非小细胞肺癌中的应用及研究进展[J].医学信息,2019,32(08):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]
YANG Long-jing,MA Hong-bo,ZHANG Xian-quan.Application and Research Progress of Anti-angiogenic Drugs in Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(04):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]